LCLAT1 and metabolic syndrome: The proposed mechanism involves an activation of ALCAT1 by dyslipidemia, which induces a remodeling of acyl chain of cardiolipin during HFD, leading to mitochondrial dysfunction and increased production of ROS, which contribute to the development of metabolic syndrome.